Common use of DESCRIPTION AND SCOPE Clause in Contracts

DESCRIPTION AND SCOPE. Medway Electronic Prescribing and Medicines Administration is a core module that will contribute to UHBristol’s HIMSS 7≡ and provide an integrated electronic prescribing capability for all general wards and outpatients across the Trust. Developed in partnership between System C and UHBristol, Medway EPMA is a completely new module, fully integrated into Medway and designed with detailed participation between clinical, pharmacy and technical users. The module will replace the paper drug chart and all prescribing and drug admin functions through to automated transfer of TTOs into the Medway-based discharge summary. Current position: • Partially funded by Tech Fund 1, the development process for this product has taken longer than expected but is now in advanced testing stage. Delivery plan: • The System C and UHBristol deployment team have completed a detailed implementation plan for the roll-out of EPMA. • Phase 1 of the roll-out will commence with the pilot of the adult functionality in the Bristol Heart Institute in Q3 17/18, followed by staged roll-out across all adult general wards by the end of Q4 17/18. • Phase 2 includes the delivery of additional technical functions and paediatric prescribing. We are currently agreeing the timescales and detailed scope for this phase, which will be completed by the end of the GDE programme term.

DESCRIPTION AND SCOPE. Medway Electronic Prescribing and Medicines Administration is a core module that will contribute to UHBristol’s HIMSS 7≡ and provide an integrated electronic prescribing capability for all general wards and outpatients across the Trust. Developed in partnership between System C and UHBristol, Medway EPMA is a completely new module, fully integrated into Medway and designed with detailed participation between clinical, pharmacy and technical users. The module will replace the paper drug chart and all prescribing and drug admin functions through to automated transfer of TTOs into the Medway-based discharge summary. Current position: •  Partially funded by Tech Fund 1, the development process for this product has taken longer than expected but is now in advanced testing stage. Delivery plan: •  The System C and UHBristol deployment team have completed a detailed implementation plan for the roll-out of EPMA. •  Phase 1 of the roll-out will commence with the pilot of the adult functionality in the Bristol Heart Institute in Q3 17/18, followed by staged roll-out across all adult general wards by the end of Q4 17/18. •  Phase 2 includes the delivery of additional technical functions and paediatric prescribing. We are currently agreeing the timescales and detailed scope for this phase, which will be completed by the end of the GDE programme term.